Benralizumab
Benralizumab
Benralizumab (pronunciation: ben-ra-li-zu-mab) is a monoclonal antibody medication used for the treatment of severe eosinophilic asthma. It is marketed under the brand name Fasenra by AstraZeneca.
Etymology
The name "Benralizumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized, "li" indicates immunomodulator, "mab" stands for monoclonal antibody, and "Benra" is a unique stem.
Mechanism of Action
Benralizumab works by binding to the interleukin-5 receptor (IL-5Rα) on the surface of eosinophils and basophils. This binding leads to apoptosis (cell death) of these cells through antibody-dependent cell-mediated cytotoxicity (ADCC).
Usage
Benralizumab is used as an add-on maintenance treatment in patients with severe eosinophilic asthma who are aged 12 years and older, and who are inadequately controlled with their current asthma medicines.
Side Effects
Common side effects of Benralizumab include headache, sore throat, and fever. Serious side effects may include allergic reactions, such as anaphylaxis.
Related Terms
- Monoclonal antibody
- Eosinophilic asthma
- Interleukin-5 receptor
- Antibody-dependent cell-mediated cytotoxicity
- Anaphylaxis
External links
- Medical encyclopedia article on Benralizumab
- Wikipedia's article - Benralizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski